Clostridium Histolyticum Collagenase - Is this revolutionary medical treatment for Peyronie's disease?

Peyronie's disease was described by Francois de la Peyronie in 1743, a battlefield surgeon and Commander of the Medical Corps of Louis XIV. The prevalence in the general population varies from 0.39-3.

4%, but increases to 7. 1% in patients between 50-69 years of age, with a reported prevalence rate of 20. 3% in men with diabetes. The disease has two distinct clinical phases; the acute and stable or chronic phases. The acute phase is characterised by painful erections with increasing penile deformity usually lasting between 3-12 months. The chronic phase is usually pain-free and characterised by stabilisation of the plaque and penile deformity. The aetio-pathogenesis of the disease remains largely unknown with local trauma, genetic and vascular factors being implicated. This article is protected by copyright. All rights reserved.

BJU international. 2015 Dec 18 [Epub ahead of print]

C Poullis, M Shabbir, I Eardley, J Mulhall, S Minhas

University College London Hospital, London, UK. , Guys Hospital, London. , St James' Hospital, Leeds, UK. , Memorial Sloan Kettering, New York, USA. , University College London Hospital, London, UK.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe